两种方案治疗晚期非小细胞肺癌的药物经济学分析  

Evaluation on Pharmacoeconomics of NP versus GP for Advanced Nonsmall-cell Lung Cancer(NSCLC)

作　　者：杨锐[1] 吴梅娜[1] 徐刚[1] 赵季文[1] 

机构地区：[1]北京大学临床肿瘤学院北京肿瘤医院暨北京市肿瘤防治研究所,北京市100142

出　　处：《中国医院用药评价与分析》2008年第12期932-934,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:用药物经济学方法分析NP和GP两种常用晚期非小细胞肺癌一线化疗方案,为临床选择疗效较好且费用较低的化疗方案提供依据。方法:选择我院2005～2007年采用NP或GP方案治疗非小细胞肺癌病历86例,应用药物经济学最小成本分析法进行分析。结果:NP和GP两种方案疗效与不良反应相近,但是成本分析显示NP低于GP,主要差异发生在药品费用上(分别为18 534.04元2、7 051.99元),药品费用经两样本检验有显著性差异(t=40,P<0.001)。结论:最小成本分析提示,NP方案与GP方案相比是比较好的晚期非小细胞肺癌的一线化疗方案。OBJECTIVE：To evaluate the pharmacoeconomics of NP versus GP as first line chemotherapy for advanced nonsmall-cell lung cancer （NSCLC） so as to optimize cheap and effective chemotherapy. METHODS： A total of 86 NSCLC patients treated by NP and GP from 2005 to 2007 collected from literature were given a cost-minimization analysis. RESULTS： There were no significant differences between NP and GP groups in either curative efficacy or side effects, but there were in drug cost, lower in NP group than in GP group （ 18 534.04 Yuan vs. 27 051.99 Yuan） （ t = 40, P 〈 0. 001 ）. CONCLUSION ： Cost-minimization analysis is suggestive of the superiority of NP to GP as first line chemotherapy for advanced NSCLC.

关 键 词：非小细胞肺癌 最小成本分析 药物经济学 

分 类 号：R979.1[医药卫生—药品]